Published in Cytometry A on November 01, 2008
The curation guidelines of the immune epitope database and analysis resource. Cytometry A (2008) 1.56
T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment. PLoS One (2012) 1.05
Antibody phage display assisted identification of junction plakoglobin as a potential biomarker for atherosclerosis. PLoS One (2012) 0.83
Measuring antigen-specific immune responses, 2008 update. Cytometry A (2008) 0.80
In Vitro Selection of Cancer Cell-Specific Molecular Recognition Elements from Amino Acid Libraries. J Immunol Res (2015) 0.75
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol (2006) 5.02
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med (2010) 2.92
A novel engineered meganuclease induces homologous recombination in yeast and mammalian cells. Nucleic Acids Res (2003) 2.49
A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. Nucleic Acids Res (2006) 2.38
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood (2010) 2.31
Engineering of large numbers of highly specific homing endonucleases that induce recombination on novel DNA targets. J Mol Biol (2005) 2.04
Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev (2009) 2.00
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther (2013) 1.89
Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother (2007) 1.86
Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells. Cytotherapy (2013) 1.43
Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol (2003) 1.41
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med (2012) 1.32
Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum Immunol (2004) 1.27
An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol (2006) 1.21
Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J Immunol (2007) 1.15
Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer. J Immunol (2008) 1.15
Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res (2009) 1.10
T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol Med (2010) 1.07
Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol (2003) 1.04
Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proc Natl Acad Sci U S A (2002) 1.03
Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol Immunother (2010) 1.03
Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther (2010) 1.03
A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma. J Immunol (2007) 1.01
T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol (2005) 1.01
T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies. Expert Opin Biol Ther (2010) 0.99
Oriented conjugates of single-domain antibodies and quantum dots: toward a new generation of ultrasmall diagnostic nanoprobes. Nanomedicine (2011) 0.96
IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother (2003) 0.96
Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther (2010) 0.95
Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody. Blood (2011) 0.95
Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther (2002) 0.94
TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets. Clin Dev Immunol (2012) 0.94
Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. J Virol (2012) 0.93
Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen. FEBS J (2009) 0.92
MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs. J Immunol (2010) 0.92
Regulation of MHC class II expression in human T-cell malignancies. Blood (2003) 0.92
Chimeric antigen receptors for T-cell based therapy. Methods Mol Biol (2012) 0.92
Clinical adenoviral gene therapy for prostate cancer. Hum Gene Ther (2010) 0.91
CD8 alpha coreceptor to improve TCR gene transfer to treat melanoma: down-regulation of tumor-specific production of IL-4, IL-5, and IL-10. J Immunol (2006) 0.89
Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel (2007) 0.88
Highly sensitive single domain antibody-quantum dot conjugates for detection of HER2 biomarker in lung and breast cancer cells. ACS Nano (2014) 0.88
Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative study. Cancer (2012) 0.88
T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness. Hum Gene Ther Methods (2014) 0.87
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol (2013) 0.87
Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells. Mol Cancer Ther (2013) 0.87
Single-domain antibody-SH3 fusions for efficient neutralization of HIV-1 Nef functions. J Virol (2012) 0.86
An oncolytic adenovirus redirected with a tumor-specific T-cell receptor. Cancer Res (2007) 0.85
T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production. Int Immunol (2006) 0.85
Strong and oriented immobilization of single domain antibodies from crude bacterial lysates for high-throughput compatible cost-effective antibody array generation. Mol Biosyst (2010) 0.83
Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro human endothelial cell selection with phage display libraries. J Immunol Methods (2004) 0.82
T-cell synapse formation depends on antigen recognition but not CD3 interaction: studies with TCR:ζ, a candidate transgene for TCR gene therapy. Eur J Immunol (2011) 0.82
Semiconductor quantum dots for multiplexed bio-detection on solid-state microarrays. Crit Rev Oncol Hematol (2009) 0.81
TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity. Mol Immunol (2010) 0.81
Gene transfer of human TCR in primary murine T cells is improved by pseudo-typing with amphotropic and ecotropic envelopes. J Gene Med (2007) 0.80
Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites. J Virol (2013) 0.80
Retracted Optimizing the exogenous antigen loading of monocyte-derived dendritic cells. Int Immunol (2005) 0.80
T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies. Hum Gene Ther (2011) 0.79
Flexible and sensitive method to functionally validate tumor-specific receptors via activation of NFAT. J Immunol Methods (2003) 0.79
Epigenetic regulation of CIITA expression in human T-cells. Biochem Pharmacol (2011) 0.79
Single-domain antibodies: a versatile and rich source of binders for breast cancer diagnostic approaches. Mol Biosyst (2012) 0.79
B and T cell imbalances in CSF of patients with Hu-antibody associated PNS. J Neuroimmunol (2008) 0.79
T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy. J Immunol Methods (2010) 0.79
Multi-component polymeric system for tumour cell-specific gene delivery using a universal bungarotoxin linker. Pharm Res (2010) 0.79
Masked selection: a straightforward and flexible approach for the selection of binders against specific epitopes and differentially expressed proteins by phage display. Mol Cell Proteomics (2013) 0.79
Affinity determination of biotinylated antibodies by flow cytometry. Methods Mol Biol (2012) 0.78
An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8α Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT. Front Immunol (2013) 0.78
Magnetic-activated cell sorting of TCR-engineered T cells, using tCD34 as a gene marker, but not peptide-MHC multimers, results in significant numbers of functional CD4+ and CD8+ T cells. Hum Gene Ther Methods (2012) 0.78
Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers. ACS Nano (2015) 0.77
TCR-engineered T cells: a model of inducible TCR expression to dissect the interrelationship between two TCRs. Eur J Immunol (2013) 0.77
mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells. Thromb Haemost (2010) 0.77
Adoptive transfer of T-cell immunity: gene transfer with MHC-restricted receptors. Trends Immunol (2002) 0.76
Phage display and selections on cells. Methods Mol Biol (2012) 0.76
State of the art in tumor antigen and biomarker discovery. Cancers (Basel) (2011) 0.75
V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1. J Acquir Immune Defic Syndr (2016) 0.75
Genetically modified T lymphocytes: more than just direct effectors. Immunotherapy (2013) 0.75
Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors. J Immunother (2009) 0.75
Twenty years of external quality assurance in clinical cell analysis--a tribute to Jean-Luc D'Hautcourt. Cytometry B Clin Cytom (2007) 0.75
Phage display and selections on purified antigens. Methods Mol Biol (2012) 0.75
Anti-Mesothelin Nanobodies for Both Conventional and Nanoparticle-Based Biomedical Applications. J Biomed Nanotechnol (2015) 0.75